Expanding Partnerships Recent partnerships with Editas Medicine and BeiGene present collaborative opportunities for joint development and commercialization of cutting-edge cellular immunotherapies, creating avenues for potential sales engagements and technology transfer.
Technology Investment Utilizing a tech stack including Google Cloud, Shoreline Biosciences demonstrates a commitment to innovative solutions. Leveraging their technology infrastructure showcases potential sales opportunities for cloud services and integration solutions.
Financial Growth With substantial funding of $140M and revenue in the range of $10M - $50M, Shoreline Biosciences has the financial stability to explore expanded research initiatives and potentially invest in new partnerships, offering sales avenues for supporting services.
Strategic Hires Key appointments of seasoned executives like Mauro as Chairman and CEO, Charles Calderaro III as CTO, and Robert Hollingsworth as CSO indicate a strong leadership team driving growth. Engaging with decision-makers in these roles can present sales opportunities for tailored solutions and collaborations.
Market Positioning Positioned as a leading biopharmaceutical company in cellular immunotherapies, Shoreline Biosciences' competitive edge presents opportunities for market expansion strategies and potential sales growth through targeted marketing campaigns and networking within the biotechnology industry.
Shoreline Biosciences, Inc. uses 8 technology products and services including Microsoft Excel, Google Cloud, HTTP/3, and more. Explore Shoreline Biosciences, Inc.'s tech stack below.
| Shoreline Biosciences, Inc. Email Formats | Percentage |
| FLast@shorelinebio.com | 50% |
| FLast@shorelinebio.com | 50% |
Biotechnology ResearchCalifornia, United States51-200 Employees
Shoreline's proprietary cell therapy technology platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced metabolic fitness and persistence of the engineered NK Cells to improve anti-cancer activity.
Company Overview
Media & News
Funding & FinancialsShoreline Biosciences, Inc. has raised a total of $140M of funding over 3 rounds. Their latest funding round was raised on Nov 02, 2021 in the amount of $140M.
Shoreline Biosciences, Inc.'s revenue is in the range of $10M$50M
Funding & FinancialsShoreline Biosciences, Inc. has raised a total of $140M of funding over 3 rounds. Their latest funding round was raised on Nov 02, 2021 in the amount of $140M.
Shoreline Biosciences, Inc.'s revenue is in the range of $10M$50M
1-888-653-2347 
support@leadiq.com